



































Statement of problem: Clinical research in hereditary muscle disease is limited by the 
absence of quantitative and objective biomarkers and outcome measures that track 
disease severity. A growing body of literature supports the use of magnetic resonance 
imaging (MRI) as a potential biomarker of disease in skeletal muscle. The work 
presented seeks to examine the viability of magnetic resonance-based biomarkers in 
muscular dystrophy. 
Methods: We conducted a systematic review of publications reporting MRI findings in 
skeletal muscle in muscular dystrophy and congenital myopathy populations. We 
subsequently performed an observational study of whole-body MRI in people with type 1 
facioscapulohumeral muscular dystrophy (FSHD) to characterize the frequency and 
severity of muscle involvement in this population. We then used a multivoxel magnetic 
resonance spectroscopy (MRS) protocol to obtain metabolite concentration profiles of 
skeletal muscle in people with FSHD. These profiles were compared to those of healthy 
volunteers. The associations between MRI/MRS measurements and clinical strength 
and function were examined using linear regression models. 
Results: A systematic review of the literature on MRI in hereditary myopathies showed 
widely variable methods of analysis and reporting. However, distinctive patterns of 
muscle involvement can be identified in some diseases. Whole-body MRI was used to 
characterize muscle involvement and sparing in FSHD. MRS further identified 
differences in muscle metabolite concentrations in people with FSHD compared to 
healthy controls. Both MRI and MRS measurements showed a significant association 




Conclusions: MRI and MRS can be used to identify patterns of disease and assess 
disease severity in the muscular dystrophies. Longitudinal studies are needed to develop 
imaging techniques as biomarkers for use in clinical trials and observational studies. 
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The muscular dystrophies 
 
The muscular dystrophies comprise a broad class of hereditary progressive 
muscle disorders. All of the muscular dystrophies are rare diseases (the most common 
form, Duchenne muscular dystrophy, occurs in 1:5,000 male births).1 However, the 
progressive weakness and multi-systemic medical complications that accompany these 
illnesses lead to a disproportionately high burden of disease in affected patients. Health 
care utilization data further indicate that there is a considerable cost of care for these 
chronic illnesses.2,3 
Mutations in any of the numerous genes involved in the structure and function of 
muscle can cause muscular dystrophy, and the numbers of disease-causing mutations 
in humans continue to grow with the increasing use of genetic testing.4 Many muscular 
dystrophies are caused by mutations in genes that encode key structural proteins in 
muscle. One of these proteins is dystrophin, a large protein that links actin (a component 
of the muscle cytoskeleton) and the dystroglycan complex located in the sarcolemma 
(the muscle cell membrane). Mutations in dystrophin cause Duchenne and Becker 
muscular dystrophy, which are among the best characterized muscular dystrophies. 
Defects in genes that engage in muscle membrane repair (dysferlin), nuclear envelope 
stability (lamin A/C), intracellular signaling (calpain), and attachment of muscle to the 
extracellular matrix (laminin alpha 2) can also cause muscular dystrophy (Table 1).5 
Muscular dystrophies can also be caused by mechanisms other than single-
gene, loss-of-function mutations. The myotonic dystrophies, for example, are repeat 
expansion diseases. In this class of disorders, excessive numbers of repeated short 
sequences of DNA produce mRNA expansions that bind and sequester proteins in the 




sequestration affects multiple systems (including the gastrointestinal, cardiac, endocrine, 
and ocular systems) in addition to muscle.6,7 Facioscapulohumeral muscular dystrophy 
(FSHD) is another example of a genetic disease that is not caused by a loss-of-function 
gene mutation. Although the pathological mechanisms that cause FSHD are 
incompletely understood, it is now recognized as a disorder of epigenetic function in 
which hypomethylation of DNA in the long arm of chromosome 4 leads to gain-of-
function effects through the unsuppressed expression of normally dormant genes.8 
 The muscular dystrophies are phenotypically diverse. The spectrum of skeletal 
muscle disease can range from clinically undetectable muscle involvement to near-
complete paralysis. The distribution of muscle weakness can also vary within the 
different types of muscular dystrophy. For instance, different mutations in the dysferlin 
gene can produce distal-predominant weakness (called Miyoshi myopathy) or a more 
typical limb-girdle phenotype characterized by proximal muscle weakness.9 At the same 
time, the muscular dystrophies have considerable clinical overlap, as mutations in 
different genes can produce similar patterns of weakness (Figure 1).4 
 
Biomarkers in hereditary muscle disease 
 
Over the past decade, several potential therapeutic interventions for muscular 
dystrophy have been developed and are currently being evaluated in clinical trials. Trials 
in muscular dystrophy rely heavily on measured strength and timed function tests as 
primary outcome measures. Although these measures are reflective of the disease state, 
our early experience in conducting clinical trials in muscular dystrophy suggests that 
better biomarkers are needed.10,11 Widely-used functional outcome measures, like the 6-
minute walk test, cannot be applied to non-ambulatory subjects, which may exclude 
potential research participants and limit the generalizability of study results. The validity 




and levels of cooperation can vary considerably between repeated measures. Several 
clinical trials have shown that the variability of the 6-minute walk test in Duchenne 
muscular dystrophy patients is larger than expected, which has significantly impacted 
sample size and power calculations for these trials.12  
Alternative outcome measures for muscular dystrophy include biomarkers from 
serum and muscle tissue, but these have limitations as well. Creatine kinase, a 
biomarker of muscle degeneration, is not uniformly abnormal in muscular dystrophy and 
can be influenced by non-disease factors such as exercise and muscle mass.13 Although 
it is currently the gold standard for ascertaining muscle pathology, skeletal muscle 
biopsy carries significant practical limitations; these procedures are invasive and provide 
only localized information on diseases that can be heterogeneous within the same 
patient or even within a single muscle. 
 
MRI in the study of muscle disease 
 
Multiple investigators have recognized magnetic resonance imaging (MRI) as a 
potential biomarker for muscle disease.14,15 The non-invasiveness and excellent safety 
profile of MR technology are highly advantageous when repeated measurements are 
required, and MRI scans can be performed in both ambulatory and non-ambulatory 
subjects. Furthermore, MRI is highly sensitive in detecting muscle inflammation and fatty 
infiltration, which are prominent pathological features of many muscle diseases. MRI is 
already becoming a standard practice in the diagnosis and management of inflammatory 
myopathies, and some studies have suggested a role for MRI in the diagnosis of 
hereditary myopathies as well.16 MRI may hold even greater promise as a research tool 
than as a diagnostic tool, as it can fulfill the need for objective outcome measures that 




The majority of MRI protocols that have been used to study muscle include T1-
weighted imaging. T1 relaxation times are based on the speed at which protons realign 
with a longitudinal magnetic field after being pushed into a transverse plane by a 
radiofrequency pulse. As protons in fat realign more quickly than protons in water, T1-
weighted images offer sharp contrast between fat and water. This not only allows 
muscles (with their high water content) to be sharply delineated in relation to the 
surrounding fat, but it also allows the observation of muscle replacement by fat as 
disease progresses. The most commonly used methods of describing the fat infiltration 
are variations on a semi-quantitative scale initially described by Murphy et al.17 Semi-
quantitative scales assign higher scores to muscles with greater levels of fat 
replacement based on visual inspection of anatomic images. It can be performed 
relatively quickly since it requires no specialized post-processing procedures and has 
been used to characterize patterns of muscle involvement and sparing in multiple types 
of muscular dystrophy.18 
T2-weighted imaging is also routinely used in the evaluation of muscle disease. 
With T2-weighted sequences, the signal intensity of each voxel is based on the T2 
relaxation time, or the speed at which protons realign in the transverse plane after a 
radiofrequency pulse. Variants of T2-weighted sequences (such as short tau inversion 
recovery and fluid attenuated inversion recovery) are “fluid-sensitive,” as the long T2 
relaxation time of free water causes it to appear bright on these sequences. This quality 
is useful in identifying edema or edema-like changes that signify the entry of free water 
into tissues; these findings are considered to be acute changes associated with 
myopathy.19 In studies of myositis, the presence of edema on MRI corresponds to 
inflammatory infiltrates that signify active disease.20 Similar inflammatory infiltration has 




dystrophy have further determined that the T2 relaxation time is elevated in muscular 
dystrophy and increases with disease severity.22 
 
The overall goal of this work is to review the literature on MRI in the 
characterization of hereditary muscle diseases and to evaluate potential new methods of 
using magnetic resonance-based techniques in the study of skeletal muscle. We begin 
with a systematic review of the literature that identifies specific patterns of fat infiltration 
in different hereditary muscle diseases. This is followed by a study of whole-body MRI in 
individuals with FSHD and a comparison of metabolic profiles derived from magnetic 
resonance spectroscopy in people with FSHD compared to unaffected controls. The 
associations between imaging-based measurements and muscle strength and function 
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Table 1: Genes known to produce hereditary myopathy 




































































FKRP  Fukutin related protein LGMD2I Glycosylation










MATR3  Matrin 3 Distal myopathy  RNA stabilization
VCP  Valosin‐containing protein Distal myopathy  Ubiquitin/ 
proteasome 
EMD  Emerin EDMD Nuclear envelope
SYNE1  Nesprin 1 EDMD Nuclear membrane 
stabilization 





LMNA  Lamin A/C LGMD1B Nuclear envelope











































SGCG  Sarcoglycan gamma LGMD2C Dystroglycan 
stabilization 
SGCA  Sarcoglycan alpha LGMD2D Dystroglycan 
stabilization 
SGCB  Sarcoglycan beta LGMD2E Dystroglycan 
stabilization 

























































































TPM2  Beta‐tropomyosin 2 Myofibrillar Muscle contraction
















CAPN3  Calpain LGMD2A Cytoskeletal repair

















































































Figure 1: Overlapping phenotypes in genes that produce limb-girdle muscular dystrophy, 
















Chapter 1: MRI patterns of muscle involvement in genetic muscle diseases:  
A systematic review 
 
Abstract 
Background: A growing body of literature supports the use of MRI as a potential 
biomarker for disease progression in the hereditary myopathies. 
Objective: To systematically evaluate patterns of fat infiltration reported in MRI studies of 
muscular dystrophy and congenital myopathy. 
Methods: Searches were performed using MEDLINE, EMBASE, and grey literature 
databases. Studies that described patterns of fat infiltration of muscles in individuals with 
muscular dystrophy or congenital myopathy were selected for full-length review. Data on 
the preferential involvement or sparing of individual muscles were extracted for analysis. 
Results: 1937 publications were screened, 59 of which met the criteria for inclusion in 
the systematic review. There were 22 distinct genetic disorders represented in this 
analysis. In most studies, preferential involvement and sparing of specific muscles were 
reported. 
Conclusions: MRI studies can identify distinct patterns of muscle involvement in the 
hereditary myopathies. Larger studies and standardized methods of reporting are 
needed to develop imaging as a diagnostic tool in these diseases. 
 
Background 
 Since the introduction of clinical magnetic resonance imaging (MRI), 
investigators in the radiographic sciences have noted the ability of MRI to produce high-
resolution anatomic images of skeletal muscle. Unlike prior imaging modalities, MRI 
provides excellent contrast between various soft tissue structures, allowing for the 




of muscle has gained wider clinical use in the inflammatory myopathies, where the 
introduction of new immunosuppressive compounds has generated a need for tools that 
can accurately diagnose and monitor response to treatment. The ability of MRI to 
distinguish between acute inflammation and chronic fatty replacement of muscle also 
provides important prognostic information.2  
In the muscular dystrophies and other hereditary myopathies, the clinical use of 
MRI as a diagnostic modality has not entered into the standard of care for multiple 
reasons. First, genetic testing has become increasingly available and affordable, and it 
offers highly specific diagnostic information that cannot be achieved with muscle 
imaging. The relative absence of large studies in this diverse patient population also 
makes the interpretation of MRI scans difficult. The absence of medical treatments for 
most hereditary muscle disorders also limits the utility of MRI, since imaging of muscle 
would not change the management of these conditions.  
Despite the known limitations, there is growing interest in using imaging (and 
MRI in particular) in research studies of hereditary muscle disease.3,4 Early trials in 
facioscapulohumeral muscular dystrophy (FSHD) have highlighted the limitations of 
existing outcome measures for muscular dystrophy.5 An objective, non-invasive measure 
that can be repeated many times could significantly improve the quality of trials in these 
diseases.  
The purpose of this review is to examine the methods with which researchers 
have used MRI to study genetic myopathies and to identify patterns of muscle 
involvement reported in the scientific literature. A systematic examination of the literature 
also provides an opportunity to identify obstacles that need to be addressed in the field 







A search of the literature was performed in accordance with methods described 
by the Cochrane Handbook for Systematic Review of Interventions.6 Controlled 
vocabulary and keyword searches were performed using the MEDLINE and EMBASE 
databases. Search terms were selected based on two concepts: 1) genetic muscle 
disease (“muscular dystrophy” or “congenital myopathy”) and 2) magnetic resonance 
imaging (“magnetic resonance imaging” or “MRI” or “magnetic resonance spectroscopy” 
or “MRS”). We did not restrict our searches with regards to publication date, allowing 
searches to include all articles published from the time of database inception to the date 
of the literature search (1/26/2016). We further evaluated reference lists from included 
articles and completed forward citation searching using the Web of Science database to 
identify additional citations. Abbreviated search strategies were used to identify relevant 
information in the Cochrane Library, OpenSIGLE (System for Information on Grey 




All titles and abstracts were reviewed, and studies were excluded based on the 
following criteria: 1) the study was not performed in humans, 2) the study did not image 
skeletal muscles in at least one limb, 3) the study did not describe a genetically distinct 
muscular dystrophy, congenital myopathy, or distal myopathy, 4) the study did not 
isolate results of MRI studies from those of other imaging modalities, 5) the study 
described only a single kindred, 6) the study described fewer than four subjects, 7) the 
methods did not report or cite a system for scoring individual muscles based on fat 
infiltration, 8) the manuscript was a review or editorial publication that did not report 




of studies that met these criteria based on titles and abstracts were downloaded and 
reviewed. Studies that did not meet these inclusion criteria after full-text review were 
subsequently excluded. 
 
Data extraction and synthesis 
The studies selected for analysis based on full-text review underwent data 
extraction. The following information about each study was collected: first author, year of 
publication, phenotype of study sample, genotype of study sample, number of MRI 
scans analyzed, regions imaged, and scoring system used for assessment of fat 
infiltration. Data on muscles that were preferentially affected and spared in each study 
population were also collected. Muscles were considered preferentially affected if they 
were defined by the authors as the earliest, most severely, or most frequently infiltrated 
by fat across the study sample. Muscles were considered preferentially spared if they 
were defined by the authors as relatively spared when compared to other muscles within 
an individual or were less frequently or severely involved across the study sample. The 
extracted data were stored in tabular form, with “+” signifying preferential involvement, “-” 
signifying sparing, “++” signifying the most preferentially involved muscle, and “--” 
signifying the most preferentially spared muscle. In instances where an entire muscle 
group was named instead of an individual muscle, all muscles within that group were 
coded equally. However, if regions comprised of more than one muscle group were 
named (for instance, “all pelvic muscles”) and the muscles within those regions were not 
explicitly defined, these groups were not coded. In studies where multiple diseases were 
described, each genetically-distinct population that met the eligibility criteria was 




The degree of heterogeneity between studies was assessed through subgroup 
analyses in which studies were stratified by disease phenotype, genotype, scoring 
technique, sample size, and regions imaged.  
 
Results 
Search results and study selection 
The search strategy identified 1937 unique citations (Figure 1).7 Screening of 
titles and abstracts resulted in the exclusion of 1694 citations. A full-text review of the 
remaining 243 articles yielded 59 that were included in the final analysis. These studies 
were published between 1993 and 2016. Because some of these texts reported more 
than one genetic disease, there were 75 discrete disease populations (“cohorts”) 
included in the analysis. These cohorts included a total of 1613 MRI scans.8-66 
 
Characteristics of included studies 
The included studies reported data from 22 different genetic myopathies (Table 
1). The number of studies for each disease varied widely (range 1 to 16), with the 
dystrophinopathies and facioscapulohumeral muscular dystrophy (FSHD) accounting for 
the largest numbers of studies (16 and 13 studies respectively). The dystrophinopathies 
and FSHD each account for approximately one third of the scans described, and the 
remaining third was split among 20 different diseases. The number of scans analyzed in 
each study also varied widely (range 4 to 269). However, most cohorts were small 
(median 11 scans, mean 21.5 scans), and only three included more than 100 scans.  
The majority of studies used a semi-quantitative scoring system with 4, 5, or 6 
grades to rank individual muscles (Table 2). Higher numerical scores were used to 
signify more extensive fat infiltration. The specific muscle characteristics and cutoffs for 




fat infiltration (similar to the scoring system described by Jungbluth) to denote changes 
in severity grade, and 29 cohorts were scored using cutoffs of 30% and 60% fat 
infiltration (similar to the Mercuri scale).51, 56 Eight cohorts did not use specific cutoff 
percentages (like the Lamminen scale).67 Only 13 of the 75 disease cohorts (8 
dystrophinopathy, 3 FSHD, and 2 myotonic dystrophy) were analyzed using alternative 
scoring systems. Eight of these 13 cohorts were described in manuscripts published 
within the past five years and utilize fully quantitative methods of determining the amount 
of fat infiltration in muscle. 
The majority of studies imaged the lower extremities, with 42 of the 75 cohorts 
exclusively imaging the lower extremities (lower leg, thigh, or pelvis). Thirty-two studies 
imaged the lower extremities and at least one other region of the body, and only two 
cohorts reported imaging of the upper extremities only. Seventeen cohorts (described in 
11 separate manuscripts) reported using whole-body MRI, or scanning of contiguous 
anatomic regions that included the arms, trunk, and legs. 
 
The dystrophinopathies 
For the purposes of pattern analysis, dystrophinopathies were divided into 3 
phenotypic subcategories (Duchenne, Becker, and carrier). While sharing a common 
genetic origin, the clinical features and natural history of these phenotypes vary widely. 
The Becker phenotype is milder than the Duchenne phenotype, while the majority of 
female carriers are asymptomatic. Despite these clinical disparities, the reported 
patterns of muscle involvement across all dystrophinopathies are similar, with at least 
half of studies reporting preferential involvement of the gluteus maximus, gluteus 
medius, and adductor magnus and sparing of the gracilis and sartorius (Table 3). The 
dystrophinopathy studies included the widest variety of scoring techniques for fat 




studies used fully quantitative techniques to characterize fat replacement. Five of these 
studies quantified the muscle fat fraction, or the percentage of muscle replaced by fat. 
 
Facioscapulohumeral muscular dystrophy 
Thirteen studies reported MRI findings in FSHD (Table 4). This group of studies 
showed the greatest anatomic diversity, with almost half of the studies imaging regions 
other than the legs. MRI of the arms is technically more challenging than imaging of the 
legs, and the number of studies that included upper extremity imaging likely reflects the 
high prevalence of upper extremity involvement in FSHD. A consistent finding among 
FSHD studies was the preferential involvement of the semimembranosus, which was 
reported to be the most severely involved muscle in nine of ten studies that scanned the 
thigh. The medial gastrocnemius and tibialis anterior muscles were the most 
preferentially affected in the lower leg, while the tibialis posterior and peroneus longus 
were frequently spared. The hip flexors (iliopsoas and iliacus) were preferentially spared 
in multiple studies. However, in contrast to Duchenne muscular dystrophy, the gracilis 
and sartorius were never reported to be preferentially spared. This may seem 
incongruous with prior observations of scans in which the gracilis and sartorius are 
spared relative to other muscles of the medial thigh in FSHD (Figure 2). One possible 
explanation is that only a subset of people with FSHD exhibit sparing of the gracilis and 
sartorius, and these muscles are not spared across the entire disease population. 
 
Observations across all studies 
Most genes had too few studies or were too heterogeneous to discern specific 
patterns of involvement (Tables 5-7). However, evaluation of imaging patterns across all 
75 cohorts yielded several notable observations. Several muscles in the posterior 




compartment (adductor magnus), and lower leg (medial gastrocnemius, soleus) were the 
most likely to be preferentially involved across all studies. The gracilis, sartorius, and 
tibialis posterior were the most frequently spared. The rectus femoris, vastus lateralis, 
adductor longus, peroneus longus, and tibialis anterior showed a mix of preferential 
involvement and sparing in different diseases. In some cases, the preferential 
involvement or sparing was disease-specific. For instance, in studies describing FSHD, 
the tibialis anterior was reported to be preferentially involved, while the peroneus longus 
was found to be preferentially spared. In the dystrophinopathies, the reverse was true, 
with multiple studies reporting sparing of the tibialis anterior and involvement of the 
peroneus longus. In most other diseases and muscles, however, there were too few 
studies or scans to define a consistent pattern of involvement. 
The diseases that were classified phenotypically as congenital myopathies or 
congenital muscular dystrophies showed distinct patterns of involvement compared to 
the dystrophinopathies, FSHD, limb-girdle muscular dystrophies, and distal myopathies. 
For instance, all of the diseases that reported preferential involvement of the sartorius 
were congenital myopathies or congenital muscular dystrophies. Similarly, the adductor 
longus was much more frequently spared in the congenital myopathies and congenital 
muscular dystrophies compared to the other forms of muscular dystrophy. 
Some radiographic features that are specific to a particular disease were noted in 
this analysis. All of the studies describing collagen VI disorders reported that the outer 
rim of the vastus lateralis was preferentially affected before the center of the muscle. 
The majority of these studies also reported a strip or notch of fat replacement in the 
center of the rectus femoris.47-49 Multiple studies describing type 1 myotonic dystrophy 
also reported a crescent-shaped pattern of involvement in the quadriceps resulting from 




vastus lateralis.43,64,68 In the majority of studies, however, no similarly distinctive patterns 
of muscle involvement or disease-defining features were reported. 
 
Discussion 
This review emphasizes several important points about the role of MRI in the 
study of muscle disease. The identification of patterns of muscle involvement and 
sparing in different types of muscular dystrophy suggests that skeletal muscle imaging 
could be used in a diagnostic capacity. While MRI does not offer the specificity of gene 
testing, there are clinical scenarios where MRI could be diagnostically useful. For 
instance, MRI may be helpful in distinguishing hereditary from acquired myopathies, 
which could impact medical management considerably. It is also possible that muscle 
MRI will have a role in determining the pathogenicity of variants of unknown significance 
identified in through genetic testing. 
The variability between studies of the same genetic disorder bears closer 
inspection. While the differences in reported patterns of muscle involvement are likely 
due in part to differences in scoring and reporting techniques, other sources of variability 
should also be considered. The increasing use of genetic testing has shown that in many 
genetic diseases, the phenotypic variability is far wider than was previously suspected. A 
number of genes, such as collagen VI and dysferlin, are associated with more than 1 
clinical phenotype.42,47 In FSHD, genotyping of family members has shown that some 
individuals who carry a disease-causing mutation are either asymptomatic or minimally 
affected.69,70 It is therefore possible that contradictory findings in imaging studies could 
relate to distinct subgroups within a disease population. 
The results of this analysis also show that the field of MRI in muscular dystrophy 
is dominated by the dystrophinopathies and FSHD. This likely reflects not only the 




patient registries, and advocacy groups. The relative paucity of scans in other diseases 
compels caution in drawing conclusions about the patterns of muscle involvement in 
these disorders, as small studies in selected populations may be subject to selection 
bias. In the extremely rare muscular dystrophies, the collection of sufficient numbers of 
scans to adequately characterize the disease population may only be achievable 
through collaborations between multiple centers around the world. 
There are some important limitations to this qualitative review. First, this review 
does not discriminate between different types of preferential involvement or sparing. 
Preferential involvement could mean the most frequently affected, the earliest affected, 
or the most extensively fat replaced muscle. Likewise, preferential sparing could mean 
that a muscle is universally spared across the cohort or relatively spared compared to 
other muscles in the same person. We relied on the authors to report preferentially 
involved or spared muscles in cases where the primary data were not provided in the 
manuscript text, and the criteria for identifying these muscles was infrequently reported. 
Despite these potential inconsistencies, the reported patterns of fat infiltration within 
individual diseases are reasonably consistent. In future observational studies and clinical 
trials, however, it will be essential to develop a uniform system of classifying and 
reporting imaging findings. 
Some hereditary myopathies were not included in this review, namely, the 
metabolic myopathies, mitochondrial myopathies, and non-dystrophic myotonias (the 
muscle ion channel disorders). While imaging studies have been performed in these 
disorders, fat replacement of muscle is not a universally reported feature in these 
diseases, and appropriate comparisons with regards to preferential muscle involvement 
could not be made.71-74 
Another potential limitation is that we were unable to stratify imaging findings 




age of onset (or duration of symptoms), age, or mutation type. At least one of the 
included studies reported differences in the patterns of muscle involvement between 
males and females.44 Our analysis also only included data on fat infiltration and did not 
take into account other features of muscle disease, such as edema-like changes, muscle 
hypertrophy, or atrophy. These factors could denote important disease subgroups and 
merit further characterization in future studies. 
The results of this review underline several factors that should be considered in 
studies using MRI in muscle disease. First is the need for greater standardization across 
all stages of imaging, from the selection of participants and imaging sequences to the 
scoring and reporting of collected images. Standardized methodologies will facilitate the 
extraction and synthesis of findings across multiple investigator groups.75 Secondly, the 
radiographic phenotypes of muscle diseases can differ considerably from clinical 
observations. For instance, several studies reported that the medial gastrocnemius 
muscle is as frequently or more frequently affected than the tibialis anterior in FSHD. 
However, foot drop is more frequently observed than calf weakness in this disease 
population. This may be due to the fact that there are multiple muscles involved in ankle 
plantarflexion, all of which are larger than the tibialis anterior. Extensive replacement of a 
single muscle may not be clinically apparent if other members of the same muscle group 
remain intact. It is also important to consider that the majority of these studies are fairly 
small case series in which a well-defined clinical population was imaged. In these cases, 
it could be expected that imaging findings would be more homogeneous. As imaging 
studies expand to include more atypical cases, we would expect the radiographic 
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Table 5: Patterns of muscle involvement and sparing in MRI studies describing limb-girdle muscular dystrophy. M and F denote 











Table 6: Patterns of muscle involvement and sparing in MRI studies describing congenital myopathy, congenital muscular dystrophy 
(CMD), Emery-Dreifuss muscular dystrophy (EDMD), distal myopathy, and oculopharyngeal muscular dystrophy (OPMD). A * 







































































































Chapter 2: Whole-body MRI in facioscapulohumeral muscular dystrophy 
 
Abstract 
Introduction: Facioscapulohumeral muscular dystrophy (FSHD) is a hereditary disorder 
that causes progressive muscle wasting. Growing knowledge of the pathophysiology of 
FSHD has stimulated interest in developing biomarkers of disease severity. 
Methods: Whole-body MRI was used to scan 24 adults with genetically-confirmed type 1 
FSHD. Muscles were scored for fat infiltration and edema-like changes. Fat infiltration 
scores were compared to muscle strength and function measurements. 
Results: Our analysis reveals a distinctive pattern of muscle involvement and sparing in 
FSHD. Averaged fat infiltration scores for muscle groups in the legs were statistically 
significantly associated with quantitative muscle strength and 10-meter walk times. 
Discussion: Advances in MRI technology allow for the acquisition of rapid whole-body 
imaging in diffuse muscle disease. This technique offers a promising disease biomarker 
in FSHD and other muscular dystrophies. 
 
Background 
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant 
muscle disease with an estimated prevalence of 3.96 per 100,000, making it one of the 
most prevalent forms of muscular dystrophy.1 Even before the genetic mutations 
associated with FSHD were identified, FSHD was considered a unique form of muscular 
dystrophy due to its characteristic pattern of muscle weakness that preferentially affects 
the face, arms, and shoulder girdle. The phenotypic spectrum of FSHD varies widely, 
with some individuals presenting in infancy with severe weakness and others remaining 




In the past ten years, there has been great progress in elucidating the genetic 
and epigenetic mechanisms of disease in FSHD. More than 95% of affected individuals 
have a deletion in the long arm of chromosome 4, but more recently, mutations in the 
SMCHD1 gene on chromosome 18 have also been found to produce the same pattern 
of weakness.2 The common mechanism of disease for both mutations is the 
hypomethylation of the 4q region. This region contains a series of 3.3 kilobase repeats 
(D4Z4 repeats), and hypomethylation of this region is believed to lead to multiple 
disease-related downstream effects.3 Each D4Z4 repeat contains a copy of DUX4, a 
gene that is expressed during development, but later chronically suppressed.4 Several 
groups of investigators have identified increased expression of DUX4 in muscle from 
individuals with FSHD, and overexpression of DUX4 in animal models has been shown 
to cause muscle toxicity.5,6 
Our increased understanding of the pathophysiology of FSHD has produced 
several promising treatment targets. However, the ability to translate basic scientific 
discoveries into treatment is limited in part by the absence of appropriate biomarkers of 
muscle disease.7 The need for biomarkers is particularly relevant in FSHD, which can be 
very slowly progressive with long periods of clinical stability. Clinical changes may occur 
over the course of years in FSHD, which increases the difficulty of performing clinical 
trials in this patient population.8 A radiological biomarker that is both noninvasive and 
sensitive to changing severity in a slowly progressive disorder like FSHD could not only 
improve our understanding of the disease and its progression, but also facilitate quicker 
clinical trials. 
Magnetic resonance imaging (MRI) is increasingly being recognized as a 
diagnostic and monitoring tool in skeletal muscle disease due to its ability to measure 
soft tissue characteristics.9,10 Although morphologic MRI has been used as an outcome 




(for instance, to the lower extremities) due to time constraints.11,12 The development of 
whole-body MRI (WBMRI) scanning technology overcomes this limitation by allowing 
investigators to scan multiple regions in the body in a clinically feasible time (typically 1 
hour or less). 
WBMRI may be particularly useful in the detection and characterization of 
skeletal muscle pathology in FSHD.  Studies using localized MRI in FSHD suggest that 
extensive subclinical disease can precede clinically detectable muscle weakness.13,14 
T1-weighted imaging has been used to identify the degree of muscle replacement by fat, 
and hyperintensity on fluid-sensitive sequences has been shown to correspond to an 
active inflammatory phase that precedes fat infiltration in FSHD.15-17 Muscle involvement 
in FSHD can be asymmetrically distributed over multiple regions of the body, however, 
and the use of localized scanning in these studies does not allow for the examination of 
the temporal patterns of muscle involvement across different regions.18  
In order to evaluate the feasibility of performing whole-body MRI in FSHD, we 
performed a cross-sectional study of adults with a wide spectrum of disease severity. 
The resultant images were used to provide descriptive data on the pattern of muscle 




Study design and setting 
The study protocol was approved by the Johns Hopkins School of Medicine 
Institutional Review Board.  Adults with FSHD were invited to participate in a single-
center, cross-sectional study. Participation consisted of an outpatient clinic visit and MRI 




scans were performed at the Johns Hopkins Hospital (both facilities are located in 
Baltimore, Maryland).  
 
Recruitment of study participants 
Study participants were recruited through IRB-approved announcements in the 
newsletter of the FSH Society, Inc., through the clinicaltrials.gov registry 
(NCT01671865), and from the clinic population of the Center for Genetic Muscle 
Disorders at the Kennedy Krieger Institute. Written informed consent was obtained from 
each participant prior to enrollment. All participants had previously undergone genetic 
testing to detect the deletion in chromosome 4 associated with type 1 FSHD. 
Participants whose genetic testing predated routine testing for the 4qA haplotype were 
not asked to undergo repeat testing if they had a clinical presentation consistent with 
FSHD. However, participants who were asymptomatic had confirmatory 4qA haplotype 
testing. Other inclusion criteria included: age ≥18 years, ability to ambulate 
independently, and ability and willingness to give informed consent. Exclusion criteria 
included standard contraindications to MRI scanning. Participants who had undergone 
scapular fixation were also excluded, as wires and other implants could create field 
distortions and artifacts in regions of interest despite being MRI-safe. Contraindications 
to MRI were ascertained through screening forms and in-person screening assessments 
performed by radiology personnel immediately prior to scanning. 
 
Clinical data collection 
Each enrolled participant was examined by the author prior to MRI. Demographic 
data (age, gender, race/ethnicity) and results of genetic testing for FSHD were 
documented.  Manual muscle testing (MMT) using the Medical Research Council (MRC) 




performed using a hand-held dynamometer (Chatillon DPP series mechanical force 
gauge). The maximum voluntary isometric force of shoulder abduction, elbow extension, 
elbow flexion, hip flexion, knee extension, and knee flexion from the better of 2 trials was 




Magnetic resonance images were acquired using a 3 Tesla Magnetom Tim Trio 
system (Siemens, Erlangen, Germany) with continuous table movement (CTM). 
Participants were placed in a head-first, supine position, and all images were acquired 
with the participant in this fixed position. Five radiofrequency coils were placed on the 
participant: an 8-channel head coil, a neck matrix coil, 2 body matrix coils (1 for the 
chest and 1 for the abdomen/pelvis) and a peripheral angiography (PA) matrix coil 
positioned over the legs. Fat-suppressed T1-weighted [repetition time (TR)/echo time 
(TE)=150/3.69ms, field of view (FOV)=50x50cm2, matrix size=320x161, inversion time 
(TI)=220ms, slice thickness=5mm, acquisition time 3:09 minutes] and Short Tau 
Inversion Recovery (STIR) (TR/TE=1200/86ms, FOV=50x50cm2, matrix size=256x256, 
TI=240ms, slice thickness = 4-6mm, acquisition time 4:10 minutes) images were 
acquired using newly-developed CTM sequences. Both sequences scanned a total 
length of 1590mm (Figure 1). Images from the thorax and abdomen were acquired 
during 12-15 second breath-holds to minimize artifact from diaphragmatic movement. 
 
Imaging outcomes 
Skeletal muscle characteristics for all study participants were scored by a single 
reviewer. All muscles visualized on T1-weighted images were scored for the degree of 




muscular dystrophies suggest that these infiltrates are composed primarily of fat, 
although regions of perimysial and endomysial fibrosis are interspersed among (and 
radiographically indistinguishable from) the fatty tissue.20,21 The scoring scale used to 
assess fat infiltration was previously described by Mercuri et al. (examples of scored 
muscles are shown in Figure 2).22 A minor modification was made to the fat infiltration 
scale; an additional score level of 5 was added to signify 100% fat infiltration on T1-
weighted imaging. This new score level was felt to be biologically significant as it would 
define a stage of disease at which no further fat infiltration could occur. For each muscle, 
the frequency of involvement, the mean fat infiltration score, and the frequency of 
asymmetric involvement across the study sample were calculated. Each of the muscles 
scored on T1-weighted imaging was classified as either involved/affected (score 2 or 
higher) or spared (score 0 or 1). Muscle pairs were defined as asymmetric if there was 
any difference in fat infiltration score between the right and left muscles in a single 
individual. Muscles were ranked by frequency of involvement, the mean fat infiltration 
scores, and the proportion of asymmetric muscle pairs. Muscles visualized on STIR 




Exploratory graphs, pairwise correlation tests, and linear regression models were 
used to study the associations between clinical outcomes and fat infiltration scores on 
MRI. Scores for individual muscles comprising the hip flexors (iliopsoas, iliacus, psoas 
major), quadriceps (vastus lateralis, vastus medialis, vastus intermedius, rectus femoris), 
hamstrings (semitendinosus, semimembranosus, long and short heads of the biceps 
femoris), biceps brachii (long and short heads), triceps (long, lateral, and medial heads), 




medial thoracic, lateral lumbar, medial lumbar) were averaged to produce a mean fat 
infiltration score for each muscle group, which was analyzed as the predictor variable. 
The muscle strength (in pounds) was regressed against the mean fat infiltration scores 
for different muscles groups using univariable regression analyses that allowed for 
clustering within individual participants (to account for possible correlation between the 
right and left legs). Univariable and multivariable linear regression models were used to 
evaluate the associations between 10-meter walk times and mean MRI scores in the 
hamstrings, hip flexors, quadriceps, paraspinal, and abdominal muscles (these muscle 
groups were selected because they were scanned in their entirety in all participants).  All 
analyses were performed using the Stata 12/IC statistical software package (StataCorp 





 Twenty-four participants (11 male, 13 female) met all screening criteria and were 
enrolled in the study (Table 1). The majority of participants (16 of 24) were recruited 
through advertising efforts; of these 16 participants, 13 were recruited through patient 
advocacy publications (both in print and online) and 3 cited the listing for this study in 
clinicaltrials.gov. Six participants were recruited from the clinic population at our center, 
and two were referred by other participants. All participants were enrolled and scanned 
between June 1, 2013 and November 30, 2014. The mean age of the study population 
was 52.5 years (standard deviation 12.3, range 20 to 72). All participants completed the 
study in its entirety and no complications were reported. For each participant, 89 to 118 





Frequency, severity, and distribution of muscle involvement 
 There was considerable variability in disease severity between participants, and 
this is reflected in the percentage of muscles that were affected within these individuals. 
Between 1.7% and 78.6% of muscles were affected in individual participants. 
Asymmetric muscle involvement was also common; over the study sample, 294 of 1327 
muscle pairs (22.2%) that were affected (either unilaterally or bilaterally) were 
asymmetrically affected. Table 2 lists the frequency, severity, and asymmetry of fat 
infiltration for each of the muscles that were scored. The most frequently and severely 
involved muscle was the semimembranosus (79% of the muscles visualized were 
affected and the mean fat infiltration score was 3.35). This is consistent with previously 
reported data using localized MRI of the lower extremities in FSHD.23 Muscles of the 
trunk (paraspinal and abdominal wall muscles) were also among the most frequently 
affected (Figure 3). 
 Examination of the frequency of muscle involvement also identified several 
muscles that were unaffected across the study sample. These include the 
supraspinatus, infraspinatus, subscapularis, teres minor, and coracobrachialis muscle in 
the upper extremity, and the obturator internus and obturator externus in the pelvis. 
Preferential muscle involvement and sparing is illustrated in the heat map (Figure 4), 
which depicts fat infiltration scores across the study sample. 
 
STIR imaging analysis 
 Only a minority of muscles in each participant were hyperintense on STIR 
imaging. Over the entire study sample, only 167 muscles out of the 2654 scored (6.3%) 
were judged to be hyperintense. However, only two of the 24 participants in the study did 
not have any STIR hyperintense muscles. In the other 22 participants, between 0.8% 




hyperintense muscle was the tibialis anterior (42.9% hyperintense), followed by the 
vastus medialis (29.2%) and medial gastrocnemius (26.1%). Although STIR 
hyperintensity was found in muscles at all levels of fat infiltration, it was most commonly 
observed in muscles with intermediate levels of fat infiltration (scores of 2 or 3) and 
rarely seen in muscles with the lowest or highest fat infiltration scores (Table 3). 
 
Associations between MRI scoring and strength/function measurements 
 Figure 5 shows quantitative muscle strength (in pounds) for six muscle groups 
(hamstrings, quadriceps, hip flexors, deltoid, triceps, biceps) plotted against mean fat 
infiltration scores for these respective muscle groups. As these muscles were measured 
on both sides, each participant contributed two data points to each graph (signified by 
color). For the upper extremity muscle groups and the hip flexors, there were few 
individuals with MRI fat infiltration scores in the more severe ranges (the hip flexor 
groups, in particular, lacked data in the severely affected range). For these muscle 
groups, stable estimates of the association between fat infiltration scores and strength 
could not be obtained. The muscle group with the widest distribution of scores was the 
hamstrings. In this group, muscle strength appears to be relatively well-preserved 
(>40lbs) for mean fat infiltration scores <2. As mean fat infiltration scores increase 
beyond 2, the strength of the corresponding muscle group declines rapidly. Within this 
range, each one-point increase in the mean fat infiltration score was associated with a 
10.9lb decline in knee flexion strength (p=0.001). 
 Examination of 10-meter walk times plotted against fat infiltration scores show a 
weak to moderate linear correlation for most muscle groups (Figure 6). A stronger linear 
correlation was demonstrated when fat infiltration scores for all of the lower extremity 
muscles were averaged and treated as a single muscle group (r=0.75, p<0.0001). 




also used a multivariable regression model that included all muscle groups of the lower 
extremity and trunk (quadriceps, hamstring, hip flexors, paraspinal, and abdominal 
muscles) as predictors. The multivariable regression model showed a statistically 
significant association between the 10-meter walk time and fat infiltration scores in both 
the hip flexors and hamstrings. In this model, each one-point increase in mean fat 
infiltration score in the hip flexor group was associated with a 2.4 second increase in the 
10-meter walk time (p=0.003). Each one-point increase in mean fat infiltration score in 
the hamstrings was associated with a 0.8 second increase in the 10-meter walk time 
(p=0.029). 
 
Analysis of asymptomatic participants 
 Five of the study participants were described as having “non-manifesting” FSHD. 
These participants did not report any signs of weakness consistent with FSHD, but had 
been found to have the genetic mutation associated with FSHD after a family member 
presented with symptoms and was diagnosed. Examination of these participants showed 
normal strength testing. However, only one of these participants was found to have no 
affected muscles on MRI. The other participants were found to have fat infiltration in the 
muscles of the trunk and leg at varying levels of severity (Figure 7). All five of the non-
manifesting participants had near complete sparing of the shoulder girdle muscles while 




            In this study, we demonstrate the utility of WBMRI in examining global muscle 
involvement in muscular dystrophy. The use of whole-body imaging in this sample 




evaluate anatomic regions that are commonly affected in FSHD – such as the shoulder 
girdle and the trunk – but are rarely imaged in their entirety and cannot be tested 
individually using manual or quantitative muscle strength testing.  The wide spectrum of 
disease severity captured using WBMRI in this study illustrates the heterogeneity of 
muscle involvement in FSHD that is only partially captured by existing disease 
biomarkers. 
One of the salient findings of this study is that WBMRI can detect muscle 
involvement before loss of strength is discernible on physical examination. In our study 
sample, we were able to detect extensive fat infiltration of muscles in participants who 
had positive genetic testing but were asymptomatic. These findings would not have been 
detectable without the use of WBMRI. As increasing numbers of mildly affected, pre-
symptomatic, or even non-manifesting patients are identified through genetic testing, 
MRI may allow clinicians to more accurately characterize their disease. 
Our study also provides new data regarding the distribution of muscle 
involvement in FSHD. Severe weakness of some muscles and sparing of others is 
frequently observed in FSHD.23,24 Whole-body imaging in our study sample expands 
upon this observation by identifying severely affected muscles (such as the paraspinal 
muscles) that cannot be easily examined in a clinical setting. Improved characterization 
of muscles that are preferentially affected may prove useful in elucidating the 
pathophysiology that produces the unique clinical findings in FSHD. Distinctive patterns 
of muscle involvement have been described in imaging studies of other muscular 
dystrophies and inflammatory muscle disorders, and the detailed characterization of 
these patterns could serve as a diagnostic tool in the evaluation of these disorders.25,26 
The pattern of muscle involvement and sparing that we observe using WBMRI 
also provides indirect information about the natural history of FSHD. Although the order 




could reasonably assume that muscles that are most frequently affected across the 
study sample are affected earlier in the disease process. The frequent involvement of 
the hamstring muscles, for instance, suggests that they are among the earliest muscles 
affected in FSHD, but the experience of our center is that knee flexion weakness is 
rarely an early clinical complaint. This is likely due to sparing of the remaining muscles in 
that muscle group. The results of our study also suggest that progression of fat 
infiltration to the remaining hamstring muscles is associated with decline in muscle 
strength. A non-invasive predictor of clinical change would be a valuable tool for 
monitoring the progression of FSHD, and the ability to obtain a global view of all the 
muscle groups in one setting would help us understand the relationship between the 
clinical and subclinical manifestations of the disease. 
Prior studies have indicated that there is an active phase of inflammatory muscle 
disease characterized by edema-like changes on fluid-sensitive MRI sequences (e.g. 
STIR), and that this phase is followed by rapid fat replacement.15,17 Indirect evidence for 
this phenomenon comes from the distribution of fat infiltration scores in this and other 
studies.27 Larger proportions of muscles were either severely affected or unaffected, 
while a relative minority of muscles fell in the intermediate levels (between 30-60%) of 
fat replacement (Table 3). This distribution suggests that the intermediate phase of 
muscle replacement occurs rapidly in FSHD, and the limited longitudinal data available 
in FSHD provides further support for this idea.17, 27 Longitudinal WBMRI studies will 
therefore be an important next step in capturing the distribution of disease over time in 
this disease population. 
There are some notable limitations to this study. Sample size is one of the most 
significant, particularly in a disease with high inter-individual variability. We anticipate 
that the small sample sizes are the primary reason for the lack of statistically significant 




quadriceps and hip flexors, as these muscles are likely to be major determinants of 
walking speed. Studies in larger numbers of patients will therefore be crucial in validating 
imaging biomarkers for use in clinical trials. We also excluded non-ambulatory patients 
and patients who had scapular fixation surgery. Both groups represent more severe 
phenotypes of FSHD and could be included in future studies. The whole-body imaging 
technique that we used also placed the arms near the edges of the magnet bore, 
resulting in distortional artifacts in these regions in a large proportion of participants. 
Another limitation of this study is the use of fat-suppressed T1-weighted imaging 
to score fat infiltration. Prior studies that have scored fat infiltration in muscle have used 
non-fat suppressed images, which offer greater contrast between fat and muscle.13 Non-
uniformity of fat suppression during scanning also may affect the appearance of muscles 
and alter scoring results. Within our study sample, only fat-suppressed T1 sequences 
were obtained in all 24 participants with sufficient image quality for scoring. Qualitative 
comparisons of the fat-suppressed and the non-fat suppressed images (when available) 
increase our confidence that the fat-suppressed T1 sequences used in this analysis 
contain sufficient uniformity of fat suppression and contrast for semi-quantitative scoring. 
Nonetheless, these technical differences may limit the comparability of this study and 
other imaging studies in FSHD. 
Another limitation to this study is the use of a semi-quantitative scoring method. 
Although this method is used frequently in MRI studies, the potential for inter-interpreter 
variability and bias is inherent to this type of rating scale. Another disadvantage to this 
method is the stratification of a continuous parameter (muscle infiltration) into only six 
levels of disease, which limits our ability to examine the association between muscle 
strength and fat infiltration within strata. Increasing evidence supports of the use of fully-
quantitative imaging techniques and algorithms (such as Dixon imaging) to quantify fat 




whole-body MRI protocols would be an important next step in developing radiological 
biomarkers for FSHD and other generalized muscle diseases. 
Despite these limitations, the wealth of information obtained using a WBMRI 
approach to FSHD promises new insight into the natural history of FSHD. Advanced MRI 
techniques and technology also provide the opportunity for rapid, standardized 
acquisition of high-quality images and a platform for the inclusion of novel imaging 
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Semimembranosus  48  38  79.2%  3.35  41.7%  18.8% 
Lower Rectus 
Abdominis 
42  31  73.8%  3.26  33.3%  0.0% 
Upper Rectus 
Abdominis 
40  29  72.5%  2.88  40.0%  0.0% 
Thoracic Medial 
Paraspinal 
48  34  70.8%  2.56  12.5%  4.2% 
Lumbar Medial 
Paraspinal 
48  33  68.8%  2.56  16.7%  12.5% 
Thoracic Lateral 
Paraspinal 
48  33  68.8%  2.69  16.7%  6.3% 
Serratus Anterior  48  30  62.5%  2.63  25.0%  8.3% 
Lumbar Lateral 
Paraspinal 
48  29  60.4%  2.42  29.2%  6.3% 
Gluteus Minimus  48  28  58.3%  2.46  33.3%  4.2% 
Latissimus  46  26  56.5%  2.50  21.7%  4.3% 
Adductor Longus  48  27  56.3%  2.02  54.2%  0.0% 
Tensor Fascia Lata  48  26  54.2%  2.29  33.3%  0.0% 
Trapezius  36  19  52.8%  2.50  5.6%  0.0% 
Adductor Magnus  48  25  52.1%  1.94  37.5%  20.8% 
Gluteus Medius  48  25  52.1%  1.67  54.2%  2.1% 
Biceps Femoris, Short 
Head 
48  23  47.9%  2.17  20.8%  0.0% 
Pectoralis Major  46  22  47.8%  1.67  26.1%  13.0% 
Semitendinosus  48  22  45.8%  1.90  29.2%  10.4% 
Rectus Femoris  48  22  45.8%  1.73  33.3%  0.0% 
Biceps Femoris, Long 
Head 
48  21  43.8%  1.81  37.5%  22.9% 
Teres Major  47  20  42.6%  1.51  34.0%  17.0% 
Vastus Medialis  48  18  37.5%  1.29  41.7%  29.2% 
Gracilis  48  18  37.5%  1.35  20.8%  4.2% 
Adductor Brevis  48  17  35.4%  1.40  25.0%  0.0% 
Medial 
Gastrocnemius 
46  16  34.8%  1.39  26.1%  26.1% 
Pectoralis Minor  46  16  34.8%  1.37  34.8%  0.0% 
Tibialis Anterior  42  14  33.3%  1.31  33.3%  42.9% 
Sartorius  48  16  33.3%  1.23  45.8%  2.1% 
Rhomboid  46  14  30.4%  1.43  26.1%  8.7% 
Vastus Intermedius  48  13  27.1%  1.02  25.0%  0.0% 




Gluteus Maximus  48  12  25.0%  0.90  16.7%  14.6% 
Triceps Medial  8  2  25.0%  1.25  0.0%  12.5% 
Quadratus Femoris  48  12  25.0%  0.92  29.2%  0.0% 
Biceps Brachii Long  36  8  22.2%  0.97  22.2%  11.1% 
Biceps Brachii Short  36  8  22.2%  1.00  27.8%  5.6% 
Extensor Digitorum 
Longus 
38  8  21.1%  0.79  31.6%  0.0% 
Triceps Long  25  5  20.0%  0.80  24.0%  20.0% 
Vastus Lateralis  48  9  18.8%  0.75  16.7%  18.8% 
Lateral 
Gastrocnemius 
46  7  15.2%  0.80  4.3%  2.2% 
Soleus  40  6  15.0%  0.88  5.0%  2.5% 
Quadratus 
Lumborum 
48  7  14.6%  0.83  20.8%  0.0% 
Iliopsoas  48  7  14.6%  0.52  20.8%  0.0% 
Piriformis  48  7  14.6%  0.65  16.7%  0.0% 
Pectineus  48  4  8.3%  0.27  16.7%  4.2% 
Deltoid Posterior  44  3  6.8%  0.34  13.6%  13.6% 
Deltoid Anterior  44  3  6.8%  0.34  9.1%  4.5% 
Popliteus  44  3  6.8%  0.23  9.1%  0.0% 
Brachialis  30  2  6.7%  0.40  13.3%  0.0% 
Tibialis Posterior  40  2  5.0%  0.33  15.0%  0.0% 
Deltoid Medial  41  2  4.9%  0.32  24.4%  4.9% 
Peroneus Longus  41  2  4.9%  0.39  24.4%  0.0% 
Iliacus  48  2  4.2%  0.17  0.0%  0.0% 
Psoas Major  48  1  2.1%  0.08  12.5%  0.0% 
Supraspinatus  21  0  0.0%  0.00  0.0%  0.0% 
Infraspinatus  47  0  0.0%  0.00  0.0%  0.0% 
Subscapularis  47  0  0.0%  0.00  0.0%  0.0% 
Teres Minor  47  0  0.0%  0.00  0.0%  0.0% 
Coracobrachialis  46  0  0.0%  0.04  0.0%  0.0% 
Obturator Internus  48  0  0.0%  0.02  4.2%  0.0% 
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Figure 2: Representative axial T1-weighted images showing asymmetric fat infiltration in 
the bilateral thighs. In the rectus femoris, there is extensive fat replacement on the right 
(score 4), while the left side is unaffected (score 0). The bilateral adductor longus 
muscles are affected, with fat infiltration scores of 4 on the right and 5 (complete 
replacement) on the left. The semitendinosus muscles are less severely affected, with 
fat infiltration scores of 3 on the right and 2 on the left. Note that fat infiltration scores are 






















Figure 3: Examples of trunk muscle involvement in FSHD. Left column: T1-weighted 
(above) and STIR (below) images showing asymmetric fat infiltration and STIR 
hyperintensity in the left lumbosacral paraspinal muscles. Upper right: Asymmetric STIR 
hyperintensity of the left serratus anterior muscle. Lower right: T1-weighted imaging 













Figure 4: Heat map of fat infiltration scores in participants with FSHD. Participants are arranged (left to right) from lowest to highest 
mean MRI score (bottom row). Muscles on the left and right sides of the body are placed to the left and right sides (respectively) of 
the labeled tick marks for each participant. Fat infiltration scores on T1-weighted MRI (from 0 to 5) and their corresponding colors are 
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Figure 6: Fitted regression lines for 10-meter walk time against mean fat infiltration MRI score in five muscle groups and all leg 





Figure 7: MRI of asymptomatic participants with FSHD confirmed by genetic testing. Left 
column: Fat-suppressed T1-weighted (above) and STIR (below) imaging of a 45-year-
old male. Thigh imaging shows asymmetric fat infiltration (scored as 4 on the right, 2 on 
the left) of the semimembranosus muscles (arrows). There is a STIR hypointense area 
in the medial left thigh due to radiofrequency artifact from the MRI coil. Right column: 
Non-fat suppressed and STIR imaging of the pelvis of a 52-year-old female. The only 













Chapter 3: An observational study of multivoxel proton magnetic resonance 
spectroscopy in facioscapulohumeral muscular dystrophy 
 
Abstract 
Introduction: Facioscapulohumeral muscular dystrophy (FSHD) is a hereditary disorder 
that causes progressive muscle wasting. Growing knowledge of the pathophysiology of 
FSHD has stimulated interest in developing quantitative biomarkers of disease severity 
that can be used in clinical trials and observational studies. 
Methods: Thirty-six adults with FSHD and 15 healthy controls underwent multivoxel 
proton magnetic resonance spectroscopy (MRS) of an axial cross-section of the mid-
thigh. The concentrations of creatine, intramyocellular lipids, extramyocellular lipids, and 
trimethylamine-containing (TMA) compounds in voxels corresponding to normal-
appearing skeletal muscle were calculated. Metabolite concentrations for participants 
with FSHD were compared with those of controls. The associations between metabolite 
concentration and muscle strength were examined. 
Results: Our analysis revealed a statistically significant reduction in the muscle 
TMA/creatine ratio in adults with FSHD compared to controls. The TMA/creatine ratio in 
the hamstrings also showed a moderate linear correlation with muscle strength. 
Discussion: MRS offers a potential method of detecting muscle pathology in FSHD prior 
to the development of fat infiltration in these muscles. Further study is needed to 
determine the longitudinal pattern of these changes in the FSHD population. 
 
Background 
One of the earliest applications of magnetic resonance technology was magnetic 
resonance spectroscopy (MRS), a technique that distinguishes metabolites by their 




multiple investigators have used MRS to study phosphorus-containing (31P) compounds 
in muscle.1 Since 31P is a component of ATP, phosphocreatine, and inorganic 
phosphate, 31P MRS has been used in the study of energy consumption and exercise-
related changes in muscle.2,3 
Studies in mice and humans have identified metabolic profiles using 31P MRS 
that are believed to be indicators of muscle degeneration and regeneration in Duchenne 
muscular dystrophy, and recent studies have reported similar findings in FSHD.4-6 In 
2010, Kan et al. showed that 31P MRS was able to differentiate between fat infiltrated 
and unaffected muscles in individuals with FSHD and controls, providing further support 
for the use of MRS in monitoring disease progression.7 More recently, Janssen et al. 
demonstrated that high-energy phosphate metabolite concentrations (specifically 
PCr/ATP) measured through MRS corresponded to the degree and rate of fat infiltration 
in specific muscles.8 
Despite the established utility of phosphorus-based MRS in the study of muscle, 
the technique is not used routinely in clinical practice. This is due in part to the need for 
specialized hardware, software, and imaging expertise to adequately perform 31P MRS 
studies. There has subsequently been interest in the development of proton (1H) MRS in 
the study of skeletal muscle.9-11 As all MRI scanners are programmed to collect 
information on proton-containing molecules, no additional hardware is required to 
perform proton MRS, and many MRI scanning systems now have built-in protocols that 
can be used to obtain spectroscopic data.  
One of the technical challenges in performing proton spectroscopy in muscle has 
been the presence of large water and fat peaks that obscure smaller peaks 
corresponding to molecules of interest. Improvements in magnetic field homogeneity, 
gradients, and water suppression have now made it possible to use proton spectroscopy 




trimethylamines (TMA) in muscle.12 Proton MRS can also be used to distinguish the 
intramyocellular (IMCL) and extramyocellular (EMCL) lipid peaks within muscle.13 As fat 
infiltration is a prominent pathological feature of the muscular dystrophies, this capability 
may be useful in characterizing pathology in these diseases. 
Another improvement in MRS technique that may enhance its utility in the study 
of muscle tissue is the ability to acquire data from multiple voxels in a single acquisition. 
Routine single-voxel spectroscopy protocols share the same disadvantages as muscle 
biopsy in that they examine small regions of large muscles and can therefore miss areas 
of disease pathology. Performing MRS in multiple voxels previously required a greater 
number of phase encoding steps, which increased the scan time at a prohibitive rate. 
However, the development of various fast MRS techniques (such as multiple-echo 
acquisition, echo-planar spectroscopy imaging, and parallel encoded MRS) has reduced 
the scan time and allowed the efficient acquisition of spectra over large regions. These 
spectra can then be mapped onto anatomic images to better appreciate spatial 
variations in the metabolic profile over large regions of tissue.14,15 
Studies of proton MRS in patients with inflammatory myopathy have shown that 
creatine concentrations are higher in patients with inflammatory myopathy compared to 
normal controls, even in muscle that appears normal on T1 and STIR (short-tau 
inversion recovery) MRI scans. These findings suggest that changes in MRS profiles 
may precede findings on traditional anatomic imaging.16 If spectroscopy can be shown to 
reliably predict loss of muscle strength and function in muscular dystrophy, it could 
benefit the field of muscular dystrophy research in multiple ways. First, it would identify 
early stages of disease pathology that precede fat infiltration, which is believed to be an 
irreversible stage of disease. Second, the ability to detect or predict short-term changes 
in muscle pathology could facilitate clinical trials in this patient population by allowing for 




To determine if muscle metabolite concentrations differ in anatomically normal-
appearing muscles in FSHD, we performed an observational cross-sectional study of 
multivoxel proton spectroscopy in adults with FSHD and unaffected healthy controls. 
 
Methods 
Study design and setting 
The study protocol was reviewed and approved by the Johns Hopkins 
Institutional Review Board. Adults (older than 18 years) with genetically-confirmed FSHD 
and healthy volunteers were invited to participate in a single-center, cross-sectional 
study. All participants were asked to undergo confirmatory gene testing for type 1 FSHD 
if it had not been done prior to enrollment. Each potential participant was screened for 
contraindications to MRI scanning (such as implanted metal devices). Participants were 
asked to return for an optional second scan between 18 and 24 months following the 
initial scan.  
 
Clinical data collection 
Demographic information (age, gender, height, weight) was collected for each 
participant. Enrollees with FSHD were asked to provide copies of their genetic testing 
results. Healthy volunteers were asked to undergo genetic testing for FSHD to confirm 
the absence of disease. On the day of each scan, participants underwent strength 
testing of the hip flexors, knee flexors, and knee extensors using hand-held 
dynamometry. A 10-meter walk time was also measured. 
 
MRI protocol 
All scans were performed at the Johns Hopkins Hospital in Baltimore, Maryland. 




(Siemens, Erlangen, Germany). Each participant was scanned in a supine, feet-first 
position. Two body matrix coils were placed over the upper and lower thighs. Multivoxel 
MR spectroscopy was performed in a single 10-mm slice centered in the mid-thigh of 
each leg (Figure 1). Shimming and water suppression were optimized using automated 
manufacturer protocols. The scanning parameters for water suppressed images were: 
TR/TE 1800/135 ms; matrix size 16 × 16; slice thickness 10 mm; field of view 16 × 16 
cm; data acquisition time 7:17 minutes per leg. The nominal voxel size was 1.0 mL. The 
echo signal was digitized with 512 data points and a spectral width of 2,000 Hz. 
Unsuppressed water images were acquired with a four-element body matrix receiver coil 
(TR/TE 1800/30ms; matrix size 16 × 16; slice thickness 10 mm; field of view 16 × 16 cm; 
data acquisition time 4:35 minutes per leg). 
 Raw spectroscopy data were exported from the scanning system as RDA files 
and processed using LCModel software. Water suppressed and unsuppressed spectra 
were used to calculate metabolite concentrations in Institutional Units (IU) and as ratios 
with respect to the creatine peak.17 
Voxels were selected for further analysis using a 2-level screening process. T1-
weighted images that were used to select regions for spectroscopy acquisition were 
examined to identify voxels that were completely enclosed within muscle. The spectra 
corresponding to these voxels were subsequently examined for spectral quality. Spectra 
were excluded if they contained excessive noise or did not demonstrate identifiable 




The distribution of metabolite concentrations was explored and examined for 




transformed, and q-q plots were used to confirm the normal distribution of the resultant 
data points. Multilevel linear regression models were used to assess differences in 
metabolite concentrations between affected and unaffected participants. Random effects 
parameters were included in the models to account for clustering within individual 
subjects and individual muscles within subjects. Mean metabolite concentrations in 
specific muscle groups were also examined with respect to strength and 10-meter walk 
time. 
For the subset of participants who returned for follow-up scans, the metabolite 
concentrations were examined using two methods. The mean concentration of each 
metabolite was calculated for each muscle. The difference in the mean metabolite 
concentration between the baseline and follow-up scans was analyzed using 
histograms, t-tests, and Bland-Altman plots. Multilevel linear regression models were 
also used to study the concentration of each metabolite studied with respect to time 
(also grouped by individual subject and muscle). Data analysis was performed using the 




A total of 51 participants were included in the observational study (36 with FSHD 
and 15 healthy controls). All participants were enrolled and scanned between April 16, 
2012 and January 30, 2015. The majority of enrollees with FSHD (25 of 36) responded 
to advertising through patient advocacy groups or clinicaltrials.gov. Of the remaining 11, 
nine were recruited from the clinic population at our center and two were referred by 
other participants. Throughout the screening process, only five potential participants who 
contacted the study team did not meet inclusion criteria for the study; four were excluded 




contraindication to MRI. Two people who did meet inclusion criteria ultimately did not 
participate; one canceled the visit due to scheduling conflicts, and another initially 
agreed to participate and later withdrew owing to claustrophobia. 
Recruitment of controls was limited to volunteers that could be matched to 
affected participants by age and gender. As participants with FSHD were accrued, they 
were divided into groups of no more than three, with each group being of the same 
gender and within 5 years of age of each other. Controls were selected so that each 
group was matched to at least one unaffected participant of the same gender whose age 
was within three years of the mean age of the group members. Among the healthy 
controls enrolled, only one was recruited through advertising. Five controls were 
unaffected relatives of clinic patients or participants in other studies at our center. The 
remaining nine controls were recruited from among employees at our center. 
 
Cross-sectional data comparing FSHD and controls 
All participants with FSHD were found to have a causative deletion on 
chromosome 4. Fourteen of the healthy controls did not have a deletion, and the single 
control that was found to have a deletion did not have the 4qA haplotype that is required 
to develop FSHD.18 The demographic features of the affected and unaffected 
participants are summarized in Table 1. Genetic testing results from participants with 
FSHD show a broad range of deletion sizes (restriction fragment sizes range from 10 to 
33 kb). 
Proton MRS was completed in both legs for most participants (3 participants had 
only one leg studied). Spectra were collected from 256 individual voxels in each leg. 
Screening for voxels that were completely enclosed within muscle excluded 78% of 
acquired voxels, and screening for spectral fit excluded an additional 13% of the 




indicated that there was insufficient field homogeneity in the majority of scans performed 
in the right lower extremity, and therefore only spectra from the left lower extremity were 
included in the analysis. The remaining 1165 voxels (representing 32 participants with 
FSHD and 14 controls) were included in the statistical analysis. No usable voxels were 
identified in 5 participants (4 affected and 1 control), and the remaining participants each 
contributed between 7 and 38 voxels to the data set. These voxels represent 12 
individual muscles of the thigh. 
 The most commonly identified metabolite peaks included trimethylamines (TMA) 
at 3.2 ppm, creatine (Cr) at 3.0 ppm, an extramyocellular lipid (EMCL) peak at 1.5 ppm, 
and an intramyocellular lipid (IMCL) peak at 1.3 ppm (Figure 2). The concentrations of 
these metabolites with respect to water and creatine were selected for further analysis. 
Multilevel regression models were used to evaluate differences in metabolite 
concentration between affected and unaffected participants while accounting for 
grouping within muscles and individual participants. These analyses demonstrated a 
statistically significant difference in TMA/Cr between affected and unaffected participants 
(p=0.001) (Figure 3, Table 2). No statistically significant differences were identified in the 
concentrations of creatine, TMA, IMCL, and EMCL or the ratios of these metabolites with 
respect to creatine (Figure 4). 
 
Comparison of metabolite concentration and clinical measurements in FSHD 
The concentrations of creatine, TMA, IMCL, and EMCL of voxels located in the 
quadriceps (vastus lateralis, vastus medialis, vastus intermedius, and rectus femoris 
muscles) and hamstrings (semitendinosus, semimembranosus, long and short heads of 
the biceps femoris) were averaged for each participant with FSHD. These muscle group 
means were then plotted against strength in these respective muscle groups. Only 




that muscle strength is greater in voxels with higher log[TMA/Cr] (r=0.62, p=0.0002). 
There was a weaker correlation between TMA/Cr concentration and the 10-meter walk 
time, but higher log[TMA/Cr] values were associated with a statistically significant 
decrease in the 10-meter walk time (r=-0.41, p=0.026) (Figure 5). No statistically 
significant association between strength or function and log[TMA/Cr] was seen in the 
quadriceps, possibly owing to a narrower range of strength measurements in this muscle 
group. No significant association with muscle strength was observed in any of the other 
metabolites studied. 
 
Longitudinal data analysis 
Longitudinal spectroscopy data was obtained from ten participants with FSHD. 
Acquisition and analysis of spectra was performed using the same protocol as the 
baseline scan. There were no statistically significant differences in knee flexion and knee 
extension strength between the baseline and 18-24 month follow-up scans. Multilevel 
regression models did not show any significant change in concentration from baseline to 
follow-up for any of the metabolites analyzed. Figure 6 shows boxplots for each 
metabolite. The difference in mean concentration between the baseline and follow-up 
studies for each muscle was not statistically significantly different from zero for any of 
the metabolites studied. Bland-Altman plots were also used to examine the distribution 




We have demonstrated that in muscles that are normal-appearing on T1-
weighted MRI, multiple metabolites can be quantified using multivoxel proton MRS. 




significant difference in the intramuscular TMA/Cr ratio. These findings are similar to 
prior studies by Hsieh et al., which also identified a decreased TMA/Cr ratio in patients 
with Duchenne muscular dystrophy compared to healthy controls.11 These investigators 
also found statistically significant differences in the TMA/water and creatine/water ratios 
comparing affected and unaffected participants, but our analysis did not reproduce this 
finding in FSHD. 
Examination of the TMA and Cr data suggest that the difference in TMA/Cr is 
primarily driven by the difference in TMA concentration, which is reduced in affected 
participants compared to controls. Although the TMA concentrations with respect to 
water did not differ significantly between affected and unaffected participants, this may 
be due to the variability in concentration found for this particular metabolite. In brain 
spectroscopy, the TMA peak is believed to contain signal from choline-containing 
compounds, including phospholipids that are implicated in cell membrane metabolism, 
and a reduced concentration of these compounds may reflect the disruption of muscle 
cell membranes that occurs in FSHD.19 Studies of muscle have also demonstrated that 
the TMA peak is comprised of several different molecules involved in muscle 
metabolism, including carnitine and acetylcarnitine.20 These compounds are involved in 
the transport of fatty acids across the mitochondrial membrane, and impairment in this 
process can result in metabolic myopathies. The relative reduction in TMA/Cr in affected 
muscle may reflect early muscle pathology that results in the loss of muscle membrane 
or mitochondrial components. 
There are some limitations in this study. An examination of outliers demonstrated 
marked differences in metabolite concentrations in the postero-lateral aspect of the right 
lower extremity compared to the left. This may be related to a scanner-specific field 
defect. To compensate for this potential confounder, we analyzed only the left lower 




detect changes in metabolite concentrations. We also did not collect data on several 
factors that are known to influence the results of MRS, including exercise levels and 
medications. Spectroscopy can also be influenced by the T2 relaxation times of the 
tissue volumes that are being measured. Our protocol did not include T2-weighted 
imaging with slices that were co-registered with the T1-weighted images used to position 
the voxels, so there was no feasible method of controlling for this potential confounder. 
Other potential limitations in this study relate to the post-processing steps. While 
it was anticipated that only a fraction of scanned voxels would be entirely enclosed 
within muscles, a large number of voxels were also excluded owing to poor spectral fit 
(Table 1). There are multiple reasons why this may have occurred, such as movement in 
the scanner. The number of voxels contributed by each participant also varied widely. 
Although our statistical model was adjusted to account for the effects of clustering, those 
participants who contributed more voxels to the dataset may still have a greater 
influence on the outcome of the analysis. 
In the limited amount of longitudinal data that was collected, we did not clearly 
identify any statistically significant changes in metabolite concentration over time in this 
subset. This observation appears to conflict with prior data from studies of MRS in 
Duchenne muscular dystrophy that shows a time-dependent change in fat and water 
concentration.21  However, this discrepancy may be related to the fact that only voxels 
corresponding to normal-appearing muscles on T1-weighted imaging were included in 
our analysis. Doing so would necessarily exclude voxels that had been replaced by fat 
between the baseline and follow-up scans. It is also possible that changes in 
spectroscopy are detectable over shorter periods of time in Duchenne muscular 
dystrophy because of the more rapid progression of disease. Further study is required to 




 Our study demonstrates that the TMA/Cr ratio in skeletal muscle of adults with 
FSHD differs significantly from those of unaffected controls. This difference was found in 
normal-appearing muscle, suggesting that it is an early pathological change. There is 
also evidence that changes in the TMA/Cr ratio are associated with muscle strength. 
Further study is needed to determine the ways in which TMA/Cr levels change over time 
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Table 2: Concentration of 7 metabolites in participants with FSHD and controls 
(represented as means and 95% confidence intervals). P-values were obtained through 







Creatine  0.00145  0.00115, 0.00184  0.00153  0.00107, 0.00219  0.802
TMA  0.00027  0.00021, 0.00035  0.00042  0.00028, 0.00063  0.065
TMA/Cr  0.17652  0.15569, 0.20014  0.25895  0.21450, 0.31262  0.001
IMCL  0.01076  0.00813, 0.01425  0.01565  0.01027, 0.02385  0.147
IMCL/Cr  7.21004  5.20847, 9.98079  10.05499  6.16943, 16.38772  0.267
EMCL  0.06963  0.04990, 0.09718  0.05519  0.03341, 0.09116  0.449






















Figure 1: Representative multivoxel grids positioned over the mid-thigh in a healthy 












Figure 2: Representative spectra from a single voxel in a participant with FSHD. The 






















Figure 3: Histogram representing the distribution of log[TMA/Cr] ratios in controls 
























Figure 4: Histograms showing the distribution of additional metabolites analyzed from 
multivoxel muscle MRS. Transparent bars represent data from controls and blue bars 























Figure 5: Fitted regression lines showing the association between hamstrings strength 
(left) and 10-meter walk time (right) and the mean log[TMA/Cr] ratio in hamstring 


























Figure 6: Box plots comparing metabolite concentration measured at baseline and after 
























Figure 7: Bland-Altman plots showing the distribution of the differences in metabolite 
concentrations between baseline and follow-up scans. Each point represents an 















Few technological advances have changed the landscape of medical diagnostics 
as much as magnetic resonance imaging. MRI offers a wealth of both visual and 
quantitative data on the pathological and molecular characteristics of biological tissue, 
and its role in medicine continues to expand. Our work seeks to take several important 
steps in the development of MRI in the study of hereditary muscle diseases. Whole-body 
MRI was used to obtain anatomic images of large regions of muscle and to uncover 
significant associations between radiographic and clinical measurements in adults with 
FSHD. We also used multivoxel magnetic resonance spectroscopy to evaluate lower 
extremity muscles in people with FSHD and controls. We were able to show that 
metabolite concentrations can differ between affected and unaffected participants, even 
in muscles that appear normal on anatomic imaging. We further determined that 
metabolite concentrations obtained via magnetic resonance spectroscopy were 
significantly associated with muscle strength. 
As we move forward in developing imaging protocols for use in clinical trials, 
researchers face several important challenges. One of these challenges is the transition 
from the primarily qualitative evaluation of radiographic data that predominates in clinical 
radiology to quantitative measurements that can enhance research studies. Researchers 
will also need to establish standardized protocols that ensure that the acquisition, 
processing, and analysis of images at different centers are comparable. Another 
challenge will be characterizing changes in radiographic measurements that occur as 
disease progresses over time. This is particularly relevant for MRI, which can often 
identify pathology before it is clinically detectable. Understanding the relationships 
between clinical and imaging observations will be crucial to the accurate interpretation of 
imaging biomarkers in clinical trials. Researchers also face the challenge of developing 




advantages of MRI is the ability to examine tissue using multiple sequences, and 
multiparametric outcome measurements that consolidate data from these sequences 
could improve their ability to detect and monitor disease pathology. 
Although extensive work needs to be done to optimize and validate imaging 
biomarkers, magnetic resonance imaging offers a valuable potential solution to the 
paucity of biomarkers and surrogate outcome measures in muscular dystrophy research. 
Overcoming this obstacle will take a major step forward in establishing clinical trial 
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2015-2020 Magnetic resonance imaging and spectroscopy biomarkers for 
facioscapulohumeral muscular dystrophy  
 K23NS091379-01 Mentored Patient-Oriented Research Career Development 
Award National Institutes of Neurological Disorders and Stroke 
 $881,794 




2010-2011 Muscle tissue collection and analysis of genetic biomarkers for FSHD 
Wellstone 
Clinical Fellowship Grant 
Biomedical Research Institute Senator Paul D. Wellstone Muscular 





PI:  Wagner K 
Role:  Clinical Research Fellow, 100% 
 
2011-2013 Magnetic Resonance Spectroscopy Imaging as a Biomarker for FSHD 
Clinical Research Training Fellowship Grant 
 American Academy of Neurology 
$130,000 
 PI:  Leung D, 80% 
 
2012-2014 Magnetic Resonance Imaging and Spectroscopy Biomarkers in FSHD 
Irene Lai Research Grant 
FSH Society  
$98,390 
 PI:  Wagner K 
Role: Co-investigator, 0% effort 
 
2014-2015 Whole-body MRI and MR spectroscopy as skeletal muscle biomarkers 
KL2TR001077 Mentored Career Development Award 
Johns Hopkins Clinical Research Scholars Program Grant 
 $58,650 
PI:  Leung D, 85% effort 
 
Research Program Building/Leadership  
 
IRB protocols – current 
 




2011-present  Magnetic Resonance and Spectroscopy Biomarkers for Facioscapulohumeral 
Muscular Dystrophy 
NA_ 00065256 
Role: Principal Investigator  
 




2014-present  A phase II randomized, double-blind, placebo-controlled, multiple ascending 
dose study to evaluate the safety, efficacy, pharmacokinetics  and 





2014-present  An Open-label, Multi-center, 48-week study with concurrent untreated 








2015-present An open-label, multi-center study to evaluate the safety and tolerability of 
eteplirsen in patients with advanced stage Duchenne muscular dystrophy 
 IRB00056437 
 Role: Sub-investigator 
 
2015-present A randomized, double-blind, placebo-controlled, dose-titration, safety, 
tolerability, and pharmacokinetics study followed by an open-label safety 
and efficacy evaluation of SRP-4045 in advanced-stage patients with 
Duchenne muscular dystrophy amenable to exon 45 skipping 
 IRB00079233 
 Role: Sub-investigator 
 
2015-2016  A Safety and Tolerability Study of Multiple Doses of ISIS-DMPKRx in 
Adults with Myotonic Dystrophy Type 1 
IRB00052515 
Role: Site Principal Investigator 
 
2015-2016 An open-label, intrapatient dose escalation study to evaluate the safety, 
tolerability, immunogenicity, and biological activity of ATYR1940 in 
patients with limb girdle and facioscapulohumeral muscular dystrophies 
 IRB00074941 
 Role: Sub-investigator 
 
2015-present A multi-site, randomized, placebo-controlled, double-blind, multiple 
ascending subcutaneous dose study to evaluate the safety, tolerability and 
pharmacokinetics of BMS-986089 in ambulatory boys with Duchenne 
muscular dystrophy 
 IRB00077885 
 Role: Sub-investigator 
 
2016-present An open-label, expanded access program intended to provide treatment with 
MP-104 (deflazacort) to U.S. children, adolescents, and/or adults with 
Duchenne muscular dystrophy 
 IRB00097299 
 Role: Sub-investigator 
 
2016-present A Phase 1b/2, Open-Label, Multiple Ascending Dose Study to Evaluate the 
Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of 
PF-06252616 in Ambulatory Participants with LGMD2I 
 IRB00089732 
 Role: Sub-investigator 
 
2016-present A Multicenter, Open-Label Extension Study to Evaluate the Long-term 
Safety of PF-06252616 in Boys with Duchenne Muscular Dystrophy 
 IRB00110715 





IRB protocols – past 
 
2010-2013 Clinical Trial of Sildenafil in Dystrophin Deficiency 
 NA_00036602 
 Role: Sub-investigator 
 
2010-2013 An exploratory study to assess two doses of GSK2402968 in the treatment of 
ambulant boys with Duchenne muscular dystrophy 
 NA_00051932 
 Role: Sub-investigator 
 
2013-2015  Duchenne Muscular Dystrophy: Double-Blind Randomized Trial to Find the 









2013-2016 A Phase lb Open-Label, Single and Multiple Ascending Dose Study to 
Evaluate the Safety, Tolerability and Pharmacokinetics  of HT-100 in 




2014-2016 An open-label extension study of HT-100 in patients with Duchenne 




2014-2016  An open-label extension study of the long-term safety, tolerability and 





2015-2016 HT-100 long-term safety and pharmacodynamics in patient with DMD who 
have completed protocols HALO-DMD-01 and HALO-DMD-02 
 IRB00068303 
 Role: Sub-investigator 
 
2015-2016 A feasibility study of outcome measures in adult LGMD2I 
 IRB00074940 
 Role: Sub-investigator 
 
2015-2016 An open-label extension study of the long-term safety, tolerability and 











Peer-reviewed publications  
1. Leung DG, Germain-Lee EL, Denger BE, and Wagner KR. "Report on the Second 
Endocrine Aspects of Duchenne Muscular Dystrophy Conference, December 1-2, 2010, 
Baltimore, Maryland, USA." Neuromuscul Disord, 2011; 21(8):594-601. 
 
Invited Review Articles 
1. Leung DG, Wagner KW. "Therapeutic Advances in Muscular Dystrophy." Invited 
Review. Ann Neurology, 2013 Sep; 74(3):404-l l. 
 
Case Reports 
2. Leung DG, Taylor HA, Lindy AS, Basehore MJ, Mammen AL. "A case of progressive 
quadriceps weakness and hyperCKemia  mimicking inclusion body myositis." Arthritis 
Care and Research, 2014; 66(2):328-333. 
 
Book Chapters, Monographs 
1. Leung DG. “Neuromuscular Diseases.” In: Hayden Gephart, M, ed. Tarascon Clinical 
Neurology Pocketbook. Burlington, MA: Jones & Bartlett Learning, 71-78, 2013. 
2. Leung DG. "Other Proven and Putative Autoimmune Disorders of the Peripheral 
Nervous System: Myasthenia Gravis." In: Johnston M, Adams H, and Fatemi SA, eds. 
Neurobiology of disease, 2nd ed. New York, NY: Oxford University Press, 714-18, 2016. 
3. Leung DG. "Neuropathies Associated with Infection or Toxic Exposure." In: Johnston 
M, Adams H, and Fatemi SA, eds. Neurobiology of disease, 2nd ed. New York, NY: 





2013-2014 Neuropsychology Department Genetics/Congenital Disorders Clinic conference, 
“Overview of muscular dystrophy,” The Kennedy Krieger Institute 
2013 Pediatric Rehabilitation Department conference, “Myopathy,” The Kennedy 
Krieger Institute 
2014-present Neurology Clerkship Lecture Series, “Numb and weak: An Introduction to 
Neuromuscular Disease,” The Johns Hopkins University School of Medicine 
2016 Physical Medicine and Rehabilitation Resident Lecture Series, “Genetic Muscle 
Disease,” The Johns Hopkins University School of Medicine 
 
Clinical Instruction 
2011-present  PM&R Residents EMG Clinic, Attending physician, The Johns Hopkins Bayview 
Medical Center 
2012-present Neurology Clerkship EMG Clinic, Attending physician, The Johns Hopkins Bayview 
Medical Center 
2013 Transition to the Wards for 2nd year medical students, Preceptor, The Johns 




2016 Clinical Skills Course for 1st year medical students, Preceptor, The Johns 
Hopkins Hospital 
 
Educational Program Building / Leadership 
2012-2015 Undergraduate Clinical Practicum in Muscular Dystrophy, Kennedy Krieger 
Institute Muscle Disorders Clinic, Preceptor 
 






Medical, other state/government licensure  
2005-2006 North Carolina, 127989 
2006-2010 California, A98786 
2010-present Maryland, D0071037  
 
Boards, other specialty certification 
2009 American Board of Psychiatry and Neurology, Neurology, #55752 
2010 American Board of Psychiatry and Neurology, Clinical Neurophysiology, 
#2185  
 
Clinical (Service) Responsibilities 
2011-present  EMG clinic, attending, ½ day per week, The Johns Hopkins Bayview Medical 
Center 
2014-present Muscle Disorders Clinic, attending, ½ day twice monthly, The Kennedy 
Krieger Institute 
 
Clinical Program Building / Leadership 
Not applicable 
 
Clinical Extramural Funding 
Not applicable 
 










Editorial Board appointments 
Not applicable 
 




05/2014 Arthritis Care and Research 
05/2014 Annals of Neurology 
05/2015 Neuromuscular Disorders 
10/2015 Muscle and Nerve 
 




2006-present Member, American Academy of Neurology 
2010-present  Member, American Association of Neuromuscular and Electrodiagnostic 
Medicine 
 









2003  Clinical Research Training Fellowship, National Institutes of Health 
2009  Neurology resident teaching award, Stanford Hospital and Clinics neurology residency  
2010  American Academy of Neurology Foundation Clinical Research Training Fellowship 
2013  KL2 Mentored Career Development Award, Johns Hopkins Clinical Research Scholars 
Program 
2016 National Institutes of Health Clinical Loan Repayment Award – National Institute of 
Neurological Disorders and Stroke 
 
Invited Talk, Panels 
05/2011 Invited speaker, FSH Society, Mid-Atlantic Member Meeting, “Update on Research 
in FSHD,” Baltimore, MD 
10/2014 Invited speaker, Muscular Dystrophy Association Make a Muscle Conference, 
“FSHD/LGMD,” Howard Community College, Columbia, MD 
10/2015 Invited speaker, American Association of Neuromuscular and Electrodiagnostic 
Medicine Annual Meeting, "MRIs as biomarkers for myopathies," Honolulu, HI 
01/2016 Invited Speaker, Interdisciplinary Clinical Genetic Conference, “MRI Biomarkers in 
Myopathy,” Baltimore, MD 
04/2016 Invited speaker/panelist, Professional Development and Careers Office, Institute for 
Clinical and Translational Research, Office of Faculty Development, “Writing 
Successful K Applications: Beyond the Basics,” Johns Hopkins University, 
Baltimore, MD 
05/2016 Invited speaker, FSH Society, Mid-Atlantic Member Meeting, “Resolaris in FSHD,” 
Baltimore, MD 
 
 
 
